혈액제재 시장 보고서 : 제품별, 항혈전 및 항응고 유형별, 항혈전 및 항응고 적응별, 지역별(2025-2033년)
Blood Preparation Market Report by Product, Antithrombotic and Anticoagulants Type, Antithrombotic and Anticoagulants Application, and Region 2025-2033
상품코드:1819918
리서치사:IMARC
발행일:2025년 09월
페이지 정보:영문 140 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계 혈액제제 시장 규모는 2024년 462억 달러에 달했습니다. 향후 IMARC Group은 2033년에는 669억 달러에 달해 2025년부터 2033년까지 3.98%의 연평균 성장률(CAGR)을 기록할 것으로 예측했습니다. 시장 확대의 배경에는 만성질환의 유병률 증가, 의료 인프라를 개선하기 위한 정부 이니셔티브 부과, 헌혈 증가로 이어지는 대중의 인식 증가, 혈액 처리 기술의 급속한 발전, 맞춤형 의료의 채택 증가 등이 있습니다.
혈액제제 시장 동향:
만성질환 증가
심혈관질환, 암, 당뇨병 등 만성질환의 증가는 혈액제제 시장 역학에 긍정적인 영향을 미치는 주요 요인 중 하나입니다. 업계 조사에 따르면, 미국에서는 약 1억 2,900만 명이 적어도 한 가지 이상의 주요 만성질환을 앓고 있는 것으로 추산됩니다. 이러한 질환은 빈혈, 응고장애, 면역부전 등의 합병증을 유발하는 것으로 알려져 있으며, 잦은 수혈, 혈소판 대체요법, 혈장치료가 필요합니다. 예를 들어, NBCUS(National Blood Collection and Utilization Survey)의 보고서에 따르면, 2021년 미국에서 10,764,000 단위의 전혈 유래 및 적혈구(RBC)가 수혈되었습니다. 또한 전 세계적으로 노인 인구가 증가하고 있으며, 이들은 만성질환 및 관련 합병증에 걸리기 쉽기 때문에 수혈의 필요성을 악화시켜이 산업의 확장을 촉진하고 있습니다.
정부 이니셔티브의 도입과 의료 인프라 개발
의료 인프라를 개선하고 안정적인 혈액 공급을 보장하기 위한 다양한 정부 이니셔티브의 도입으로 혈액제제 시장 규모가 확대되고 있습니다. 헌혈을 장려하고, 혈액은행 시설을 개선하고, 혈액 제제의 전반적인 안전성과 가용성을 높이기 위한 노력에 대한 정부의 투자에 중점을 두면서 시장 성장을 촉진하고 있습니다. 예를 들어, 인도 정부(GOI)는 수혈 서비스를 통해 공공 및 자선 부문의 1131개 혈액은행에 인력, 혈액백 및 검사 키트 조달, 자발적 헌혈(VBD) 캠프 실시, 정보 교육 및 커뮤니케이션(IEC) 활동 등을 지원하고 있습니다. 또한, 정부는 혈액제제의 품질과 안전성을 보장하기 위해 엄격한 조치를 시행하고 있으며, 이는 의료진과 환자의 신뢰를 구축하는 데 도움이 되고 있습니다. 예를 들어, e-RaktKosh는 혈액은행을 모니터링하기 위한 인도 정부의 이니셔티브로, 모든 혈액은행을 단일 네트워크로 상호연결하는 통합 혈액은행 관리 정보 시스템입니다.
헌혈에 대한 인식 제고와 헌혈 증가
헌혈의 중요성에 대한 인식이 높아지고 전 세계적으로 헌혈자 수가 증가함에 따라 혈액제제 시장 점유율이 증가하고 있습니다. 미국에서는 매년 약 680만 명이 헌혈을 하고 1,360만 단위의 전혈과 적혈구가 수집되고 있습니다. 또한, 정부, 비정부기구(NGO) 및 의료 서비스 제공자가 주도하는 공중보건 캠페인 및 이니셔티브의 도입은 헌혈의 중요성을 인식시키고 시장 성장을 촉진하고 있습니다. 이와 함께 선진국과 신흥국에서 혈액제제에 대한 수요가 증가함에 따라 보다 체계적이고 조직화된 헌혈 시스템을 통해 안정적이고 안정적인 혈액 공급을 보장하는 것이 시장 성장을 견인하고 있습니다.
The global blood preparation market size reached USD 46.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 66.9 Billion by 2033, exhibiting a growth rate (CAGR) of 3.98% during 2025-2033. The market is expanding due to the rising prevalence of chronic diseases, imposition of government initiatives that improve healthcare infrastructure, growing public awareness leading to increased blood donations, rapid advancements in blood processing technology, and the increasing adoption of personalized medicine.
Blood Preparation Market Trends:
Increasing Prevalence of Chronic Diseases
The rise in chronic diseases, including cardiovascular conditions, cancer, and diabetes, is one of the major factors positively impacting the blood preparation market dynamics. As per industry research, an estimated 129 million people in the U.S. have at least one major chronic disease. These diseases are known to result in complications such as anemia, clotting disorders, and immune system deficiencies, which require frequent blood transfusions, platelet replacement therapy, and plasma treatments. For instance, according to the National Blood Collection and Utilization Survey (NBCUS) report, in 2021, 10,764,000 units of whole blood-derived and apheresis red blood cells (RBCs) were transfused in the United States. Moreover, the growing geriatric population across the globe, exacerbating the need for blood transfusion as these individuals are more prone to chronic illnesses and associated complications, is bolstering the expansion of this industry.
Introduction of Government Initiatives and Healthcare Infrastructure Development
The introduction of various government initiatives to improve healthcare infrastructure and ensure a stable blood supply is enhancing the blood preparation market size. The increasing government focus on investing in initiatives that promote blood donation, improve blood bank facilities, and enhance the overall safety and availability of blood products is boosting the market growth. For instance, the Government of India (GOI), through blood transfusion services, has been supporting 1131 blood banks in the public and charitable sector with respect to manpower, procurement of blood bags and testing kits, conduction of voluntary blood donation (VBD) camps, and information education communication (IEC) activities. In addition, governments are implementing stringent measures to ensure the quality and safety of blood products, which helps build trust among healthcare providers and patients. For example, e-RaktKosh, an initiative of the Government of India to monitor the blood banks, is an integrated blood bank management information system that interconnects all the blood banks into a single network.
Growing Awareness and Increasing Blood Donations
The growing awareness about the importance of blood donation and the increasing number of blood donors across the globe are boosting the blood preparation market share. Each year, an estimated 6.8 million people in the U.S. donate blood, and 13.6 million units of whole blood and red blood cells are collected. Moreover, the introduction of public health campaigns and initiatives led by governments, non-governmental organizations (NGOs), and healthcare providers to educate the public about the life-saving importance of donating blood is bolstering the market growth. Along with this, the growing demand for blood products in developed and developing countries that is leading to more structured and organized blood donation systems, which ensure a steady and reliable supply of blood, is fueling the market growth.
Blood Preparation Market Segmentation:
Breakup by Product:
Whole Blood
Red Cells
Granulocytes
Plasma
Platelets
Blood Components
Whole Blood Components
Packed Red Cells
Leukocyte Reduced Red Blood Cells
Frozen Plasma
Platelet Concentrate
Cryoprecipitate
Blood Derivatives
Whole blood accounts for the majority of the market share
As per the blood preparation market analysis, whole blood dominated the market due to its widespread use in various medical treatments, including surgeries, trauma care, and transfusions for patients with severe anemia or blood loss. Moreover, it contains all essential components, such as red cells, white cells, platelets, and plasma, making it versatile for multiple clinical applications. Besides this, the growing demand for whole blood in emergency and critical care settings, coupled with its crucial role in life-saving procedures, is contributing to the market growth.
Breakup by Antithrombotic and Anticoagulants Type:
Platelet Aggregation Inhibitors
Glycoprotein Inhibitors
COX Inhibitors
ADP Antagonists
Others
Fibrinolytics
Tissue Plasminogen Activator (TPA)
Streptokinase
Urokinase
Anticoagulants
Heparins
Vitamin K Antagonists
Direct Thrombin Inhibitors
Direct Factor Xa Inhibitors
Anticoagulants holds the largest share of the industry
Based on the blood preparation market overview, anticoagulants accounted for the largest market, driven by their critical role in preventing and treating blood clots, which are common in conditions such as deep vein thrombosis, pulmonary embolism, and atrial fibrillation. Moreover, anticoagulants are essential for managing clot-related disorders and reducing the risk of strokes and heart attacks. Besides this, their frequent use in surgical procedures and long-term treatments for patients with cardiovascular conditions is enhancing the market growth. Along with this, the increasing geriatric population, which is more prone to clotting disorders, and the development of newer anticoagulant therapies that offer improved safety and efficacy profiles are boosting the blood preparation market growth rate.
Breakup by Antithrombotic and Anticoagulants Application:
Thrombocytosis
Pulmonary Embolism
Renal Impairment
Angina Blood Vessel Complications
Others
Thrombocytosis represents the leading market segment
According to the blood preparation market forecast, thrombocytosis represented the largest share in the market, due to the increasing prevalence of conditions that cause elevated platelet counts, such as myeloproliferative disorders. Moreover, thrombocytosis often leads to excessive blood clot formation, which can result in severe complications like strokes or heart attacks. Anticoagulants and antithrombotic therapies are critical for managing this condition by preventing abnormal clotting. Along with this, the growing awareness of thrombocytosis, rapid advancements in diagnostic tools, and the availability of targeted anticoagulant treatments are driving the market growth.
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest blood preparation market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for blood preparation.
As per the blood preparation market report, North America is leading the market, driven by its well-established healthcare infrastructure, high prevalence of chronic diseases, and significant healthcare spending. Moreover, the growing demand for blood products, fueled by the growing incidence of conditions such as cancer, cardiovascular diseases, and anemia, which require regular blood transfusions and platelet therapies, is bolstering the market growth. Besides this, the introduction of advanced medical technologies, a strong emphasis on blood safety, and a large network of blood donation centers in the region are acting as major blood preparation market drivers.
Competitive Landscape:
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the blood preparation industry include Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., LEO Pharma A/S, Pfizer Inc., Portola Pharmaceuticals Inc. (Alexion Pharmaceuticals Inc.), Sanofi S.A., etc.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
The leading players in the market are focusing on strategic collaborations, product innovations, and expanding their geographical presence to strengthen their market positions. They are investing in research and development (R&D) to introduce advanced blood products and technologies aimed at improving safety and efficacy. Moreover, several firms are enhancing their production capabilities to meet the rising demand for plasma-derived therapies and other blood components. Besides this, they are forming partnerships with hospitals, blood banks, and healthcare institutions to secure stable supply chains and improve accessibility.
Key Questions Answered in This Report
1.What was the size of the global blood preparation market in 2024?
2.What is the expected growth rate of the global blood preparation market during 2025-2033?
3.What are the key factors driving the global blood preparation market?
4.What has been the impact of COVID-19 on the global blood preparation market?
5.What is the breakup of the global blood preparation market based on the product?
6.What is the breakup of the global blood preparation market based on the antithrombotic and anticoagulants type?
7.What is the breakup of the global blood preparation market based on the antithrombotic and anticoagulants application?
8.What are the key regions in the global blood preparation market?
9.Who are the key players/companies in the global blood preparation market?
Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Blood Preparation Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product
6.1 Whole Blood
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Red Cells
6.1.2.2 Granulocytes
6.1.2.3 Plasma
6.1.2.4 Platelets
6.1.3 Market Forecast
6.2 Blood Components
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Whole Blood Components
6.2.2.2 Packed Red Cells
6.2.2.3 Leukocyte Reduced Red Blood Cells
6.2.2.4 Frozen Plasma
6.2.2.5 Platelet Concentrate
6.2.2.6 Cryoprecipitate
6.2.3 Market Forecast
6.3 Blood Derivatives
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Antithrombotic and Anticoagulants Type
7.1 Platelet Aggregation Inhibitors
7.1.1 Market Trends
7.1.2 Key Segments
7.1.2.1 Glycoprotein Inhibitors
7.1.2.2 COX Inhibitors
7.1.2.3 ADP Antagonists
7.1.2.4 Others
7.1.3 Market Forecast
7.2 Fibrinolytics
7.2.1 Market Trends
7.2.2 Key Segments
7.2.2.1 Tissue Plasminogen Activator (TPA)
7.2.2.2 Streptokinase
7.2.2.3 Urokinase
7.2.3 Market Forecast
7.3 Anticoagulants
7.3.1 Market Trends
7.3.2 Key Segments
7.3.2.1 Heparins
7.3.2.2 Vitamin K Antagonists
7.3.2.3 Direct Thrombin Inhibitors
7.3.2.4 Direct Factor Xa Inhibitors
7.3.3 Market Forecast
8 Market Breakup by Antithrombotic and Anticoagulants Application
8.1 Thrombocytosis
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Pulmonary Embolism
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Renal Impairment
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Angina Blood Vessel Complications
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Others
8.5.1 Market Trends
8.5.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Baxter International Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Boehringer Ingelheim International GmbH
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 Bristol-Myers Squibb Company
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Daiichi Sankyo Company Limited
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 GlaxoSmithKline PLC
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Johnson & Johnson Services Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.7 LEO Pharma A/S
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 SWOT Analysis
14.3.8 Pfizer Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Portola Pharmaceuticals Inc. (Alexion Pharmaceuticals Inc.)
